Novartis dystrophy data tee up regulatory talks on Avidity drug
Novartis has reported a phase 1/2 win for one of the jewels of its $12 billion Avidity Biosciences buyout,…
Novartis invests US$200min lacklustre Parkinson’s target
Arrowhead’s preclinical siRNA programme ARO-SNCA for the treatment of Parkinson’s and other synucleinopathies is worth an upfront payment…
What’s next in Neuroscience drug discovery
Bryan Laffitte has had a long career at Novartis in San Diego, California—with some twists and turns. After…